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Bluetongue virus (BTV), a member of Orbivirus genus, is transmitted by biting midges 22 
(gnats, Culicoides sp) and is one of the most widespread animal pathogens, causing serious 23 
outbreaks in domestic animals, particularly in sheep, with high economic impact. The non-24 
enveloped BTV particle is a double-capsid structure of seven proteins and a genome of ten 25 
double-stranded RNA segments. Although the outermost spike-like VP2 acts as the 26 
attachment protein during BTV entry, no specific host receptor has been identified for BTV. 27 
Recent high-resolution cryo-electron (cryoEM) structures and biological data have suggested 28 
that VP2 may interact with sialic acids (SAs). To confirm this, we have generated protein-29 
based nanoparticles displaying multivalent VP2 and used them to probe glycan arrays. The 30 
data show that VP2 binds α2,3-linked SA with high affinity but also binds α2,6-linked SA. 31 
Further, Maackia Amurensis Lectin II (MAL II) and Sambucus Nigra Lectin (SNA), which 32 
specifically bind α2,3-linked and α2,6-linked SAs respectively, inhibited BTV infection and 33 
virus growth in susceptible sheep cells while SNA alone inhibited virus growth in Culicoides-34 
derived cells. A combination of hydrogen deuterium exchange mass spectrometry and site-35 
directed mutagenesis allowed the identification of the specific SA binding residues of VP2. 36 
This study provides direct evidence that sialic acids act as key receptor for BTV and that the 37 
outer capsid protein VP2 specifically binds SA during BTV entry in both mammalian and 38 
insect cells. 39 
 40 
Importance 41 
To date no receptor has been assigned for non-enveloped bluetongue virus. To determine if 42 
the outermost spike-like VP2 protein is responsible for host cell attachment via interaction 43 
with sialic acids, we first generated a protein-based VP2-nanoparticle, for the multivalent 44 
presentation of recombinant VP2 protein. Using nanoparticles-displaying VP2 to probe a 45 















































Lectin inhibitors targeting both linkages of sialic acids showed strong inhibition to BTV 47 
infection and progeny virus production in mammalian cells, however the inhibition was only 48 
seen with the lectin targeting α2,6-linked sialic acid in insect vector cells. In addition, we 49 
identified the VP2 sialic acid binding sites in the exposed tip domain. Our data provides 50 
direct evidence that sialic acids act as key receptors for BTV attachment and entry in to both 51 
mammalian and insect cells. 52 
 53 





























































Non-enveloped orbiviruses with complex capsid structures represent an intriguing system for 69 
understanding virus entry mechanisms. Although the Orbivirus genus belongs to Reoviridae 70 
family, these viruses are uniquely vectored to wild and domestic animal species (e.g., sheep, 71 
cattle, horses, deer, etc.) by arthropods (gnats, ticks, or mosquitoes). Bluetongue virus 72 
(BTV), the prototype of the genus, with 28 serotypes, is one of the most widespread animal 73 
pathogen and acts as an important representative of this class of large non-enveloped viral 74 
pathogens. BTV is transmitted by Culicoides species, gnats (biting midges) between its 75 
animal hosts, and often causes serious periodic outbreaks particularly in sheep and cattle, 76 
with high economic impact.  77 
BTV is structurally highly complex with a genome of ten double-stranded RNA (dsRNA) 78 
segments (S1-S10) enclosed by four layers of different proteins. Ten genomic segments 79 
encode seven structural proteins (VP1-VP7) and four non-structural proteins (NS1-NS4). 80 
The outer capsid is formed by two consecutive layers of proteins, the outermost VP2 and the 81 
slightly less exposed VP5, and both proteins attach to an underlying VP7 layer which coats 82 
the VP3 core. The remaining three structural proteins (VP1, VP4 and VP6) form the 83 
enzymatic interior of the virus together with genomic RNA. Recent atomic-resolution 84 
structures have revealed that 120 VP2 molecules form 60 trimers and that each monomer 85 
consists of three distinct domains (hub, body and tip), displayed as triskelion-like spikes, 86 
each blade of which (viz., the tip domain) protrudes 4 nm from the surface of the particles 87 
while the hub and body base sits on the underlying VP5 trimers (1). The structural 88 
configuration of VP2 is consistent with it biological functions, as it is the host attachment 89 
protein, and also the viral antigenic determinant of serotype specificity (2). Upon attachment, 90 
VP2 facilities the clathrin-mediated endocytosis of virion particles. In the early endosome 91 
VP2 senses the low pH via a unique zinc finger and consequently changes conformation and 92 















































proceeds to the late endosome where the acidic pH triggers drastic conformation change to 94 
enable membrane penetration and release of the viral core into the cytoplasm (1, 3, 4).  95 
While much molecular and structural study has been undertaken on the action of VP2 and 96 
VP5 in cell entry, to date no receptor has been assigned for BTV or any other orbiviruses, 97 
although our previous studies have suggested that cell surface sialic acids, and possibly 98 
additional receptors may be involved (1, 5). Arboviruses generally do not rely on a single 99 
specific host receptor, rather they use common cellular ligands, such as Ca2+-dependent (C-100 
type) lectins, immunoglobulin fragment crystallisable-gamma (Fcγ) receptors and tyrosine-101 
protein kinase receptor Axl (6) 102 
Sialic acids are known to be involved for attachment and entry of other non-enveloped and 103 
enveloped viruses, such as adenoviruses, rotaviruses and influenza viruses (7-9) and our 104 
previous studies indicated that BTV binds glycophorin A, which contains high levels of sialic 105 
acids (10). Further, the lectin wheat germ agglutinin (WGA), which binds specifically to N-106 
Acetyl-D-glycosamine (GlcNAc), had been shown to block BTV binding to the cells (5, 10). 107 
However, there is no direct evidence that VP2 binds sialic acids and if so what types of sialic 108 
acid may serve as BTV ligands during virus entry. 109 
In this report, to determine that sialic acid is a cellular ligand for BTV and that VP2 is directly 110 
responsible for this interaction. To do this we first generated recombinant VP2 as protein 111 
nanoparticles (Fc-VP2-PNP) to increase avidity through multivalent interactions as reported 112 
for coronavirus spike protein (11). Using these nanoparticles, it was possible to obtain direct 113 
evidence of specific interaction between VP2 and specific sialic acids, particularly its 114 
specificity for α2,3 and α2,6 linkages. Further, we determined the sialic acid preference used 115 
by BTV for mammalian versus vector Culicoides cells. Lastly, we identified the sialic acid 116 


















































Multivalent presentation of recombinant VP2 protein on the nanoparticles  121 
BTV is capable of agglutination of a variety of animal and human red blood cells (RBCs) in 122 
vitro. Hemagglutination specificity for certain erythrocytes has been reported for different 123 
BTV serotypes with variable intensity indicating the activity is serotype-dependent (12, 13). 124 
Our previous use of recombinant purified BTV-10 VP2 confirmed that VP2 is responsible for 125 
binding to glycophorin on red blood cells and hemagglutanation activity (10). However, the 126 
hemagglutination activity of purified VP2, as a soluble protein, is generally very low when 127 
compared to the virion particle (10) and is too weak to investigate the interaction of VP2 with 128 
sialic acid receptors (14). To overcome the low affinity of VP2 binding to sialic acids, we 129 
designed multi-copy VP2 self-assembled into a nanoparticle similar to that reported for 130 
MERS-CoV S1 protein, which then showed enhanced hemagglutination activity (11). The 131 
nanoparticle is a 60-meric self-assembled particle of Lumazine Synthase (LS) from the 132 
hyperthermophile Aquifex aeolicus. The N-terminus of LS is fused with domain B of protein A 133 
(pA) from Staphylococcus aureus which has a high affinity for the Fc fragment of human IgG 134 
(15). Accordingly, a construct was made to express the pA-LS nanoparticle protein as a 135 
secreted protein from transfected HEK293T cells with an added N-terminal streptavidin tag 136 
to facilitate affinity purification. The purified nanoparticles were analysed by SDS-PAGE 137 
followed by coomassie staining. The protein content of the nanoparticles showed a monomer 138 
molecular mass ~ 25kDa, as predicted (Fig.1A). To allow binding of VP2 to the nanoparticle, 139 
the amino terminus of VP2 was tagged with the Fc sequence from human IgG and a 140 
streptavidin tag II (WSHPQFEK) for affinity purification and the subsequent fusion protein 141 
expressed using the baculovirus expression system. Analysis of purified Fc-VP2 protein by 142 
SDS-PAGE showed that VP2 largely existed in its trimeric form, however, in the presence of 143 
reducing agent or heat treatment the protein converted to the monomeric form (Fig.1B). To 144 
prepare VP2-nanoparticles, 6μg of pA-LS nanoparticles and 20μg of Fc-VP2 were incubated 145 















































analyzed by glycerol gradient ultracentrifugation. A clear shift was apparent of Fc-VP2 from 147 
the top layer to the middle-lower layer of the gradient in the presence of pA-LS compared to 148 
Fc-VP2 in the absence of pA-LS, indicating the formation of a nanoparticle complex (Fig.1C). 149 
We calculated the amounts of pA-LS and Fc-VP2 in fractions 7 to 10 by densitometry, 150 
suggesting a molar ratio between 1:0.2 to 1:0.29 of pA-LS and Fc-VP2 in the complex. 151 
 152 
VP2-nanoparticles (Fc-VP2-PNPs) enhance the hemagglutination and the glycophorin 153 
binding activities 154 
To examine if the VP2 nanoparticle could hemagglutinate sheep RBCs, a combination of 155 
different amount of Fc-VP2 and 1 or 2 μg of pA-LS was optimized for hemagglutination 156 
activity. The combination of 1 μg pA-LS and 1.25 μg Fc-VP2 (equivalent to a molar ratio of 157 
1:0.25) exhibited the maximum HA titre of 512 with sheep RBCs. In contrast, nanoparticles 158 
lacking Fc-VP2, as a control, failed to show any hemagglutination activity (Fig.2A). When 2.5 159 
μg of Fc-VP2 was incubated with decreasing amounts of nanoparticles (1, 0.5, 0.25 and 160 
0.125 μg) the HA titres also decreased. However, increasing the Fc-VP2 amount in the 161 
nanoparticles to 4 μg did not significantly increase the HA titre, indicating that nanoparticles 162 
have been saturated for their maximum binding capacity (Fig.2B). The optimized 163 
combination of Fc-VP2 and pA-LS, which exhibited the maximum HA titre, suggested that 164 
approximately five of Fc-VP2 trimers can be accommodated on each of the 60-mer pA-LS 165 
nanoparticles forming Fc-VP2-PNP. Fc-VP2 alone without nanoparticles exhibited a very low 166 
HA titre, of only ~4 units (Fig.2B) consistent with a previous study (10) and an inability to 167 
crosslink the RBCs. Thus, nanoparticles presenting VP2 have significantly increased 168 
hemagglutination activity.  169 
To determine whether the multivalent Fc-VP2 nanoparticles could increase the interaction of 170 
VP2 to human glycophorin A, the predominant sialoglycoprotein on human red blood cells, 171 















































mixtures of 2 μg pA-LS and different amounts of purified Fc-VP2 or Fc-VP2 alone as before. 173 
While binding of VP2 alone was minimal, binding of the Fc-VP2-PNPs was significantly high 174 
and was dose-dependent, with the maximum binding at the molar ratio about 1:0.2 of pA-LS 175 
and Fc-VP2 (Fig.2C). These data confirm that VP2-nanoparticles significantly increase sialic 176 
acid binding capacity when compared to VP2 protein alone. 177 
 178 
Does VP2 recognise specific sialic acid for cell attachment? 179 
The enhanced sialic acid binding affinity of Fc-VP2-PNPs led us to use these particles to 180 
identify the VP2 preference for specific sialic acid linkages. To this end, we probed an array 181 
of 562 glycans (16) with the Fc-VP2-PNPs and compared the binding profile to uncoated 182 
PNPs alone as control. As shown in the figure 3, the results showed clearly that there is a 183 
preferential binding to sialylated glycans by the Fc-VP2-PNPs complex compared to the 184 
PNPs alone, which did not bind to any sialylated glycan structures (Supplementary Table.1), 185 
indicating the specific interaction between VP2 and sialylated glycans. 186 
Based on the glycan array data, VP2 bound to both Neu5Ac and Neu5Gc sialoglycans with a 187 
preference for Neu5Ac (Fig.3). Further, it preferentially bound to the short, unbranched α2,3-188 
linked sialotrisaccharides (glycan #45 and #277) and α2,6-linked (glycan #267, #266 and 189 
#278) sialoside, as well as to long, branched α2,3-linked sialosides with a minimum 190 
extension of an N-Acetyllactosamine (LacNAc) tandem repeats. A low level of binding was 191 
observed to a number of α2,3/α2,6-linked and α2,8-linked sialosides but the preferential 192 
binding was clearly to α2,3-linked sialosides (Fig.3). Our data are consistent with earlier 193 
reports that both α2,3- and α2,6-linked sialic acids could be utilized as receptors by BTV for 194 
attachment during its entry into the host cells. 195 
 196 
















































To investigate further if BTV used different sialic acids for different host cells, a series of 199 
mammalian cells were examined for BTV infection in the presence of specific lectin 200 
inhibitors, Maackia Amurensis Lectin II (MALII), which binds α2,3-sialic acid and Sambucus 201 
Nigra Lectin (SNA), which prefers to bind α2,6-sialic acid. Prior to an assessment of SA 202 
specificity, we first examined the distribution of α2,3- and α2,6-linked sialic acids on the 203 
surface of three different mammalian cells, BSR (BHK-21 derived) cells that are used for 204 
BTV infection routinely in the laboratory and the two different BTV-susceptible host cell 205 
lines, PT (sheep) cells and MDBK (steer) cells by immunofluorescence microscopy using 206 
FITC-conjugated MALII and SNA. All three types of cells showed a predominant distribution 207 
of α2,6-linked sialic acids over α2,3-linked sialic acids, although PT cells exhibited abundant 208 
distribution of both α2,3- and α2,6-linked sialic acids compared to the other two mammalian 209 
cell lines (Fig.4A). The data was further confirmed by flow cytometry analyses. As shown in 210 
Figure 4B, α2,6-linked sialic acids of all three cell lines exhibited higher level of median 211 
fluorescence intensity (MFI) of α2,6-linked sialic acids compared to that of α2,3-linked sialic 212 
acids. 213 
All three cells were then pre-incubated with 100, 200, 400, 600 or 800 μg/ml of MALII or 214 
SNA, and a combination of both lectins at 400μg/ml of each lectin, prior to infection with 215 
BTV. An MTT (2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) 216 
cytotoxicity assay showed that there was no significant cytotoxicity at the concentrations 217 
tested (Fig. 5A). Both MALII and SNA lectin competitors inhibited progeny virus production in 218 
a dose-dependent manner in all three types of cells. At 400μg/ml concentration, MALII 219 
showed approximately 63%, 88% and 59% inhibition of virus infection in BSR, PT and 220 
MDBK cells respectively while SNA showed more than 90% inhibition in all cells. With the 221 
combination of both lectins at the concentration of 400μg/ml, inhibition was almost 100% in 222 
all three mammalian cell lines (Fig. 5B). These results are consistent with the observed 223 
distribution of α2,3- and α2,6-linked sialic acids in the three cell lines and suggest that BTV 224 















































prove that blocking cell surface sialic acids prevents viral binding, we compared the viral 226 
binding to PT cells in the presence or absence of lectins. PT cells were pre-treated with 227 
400μg/ml of MALII, 400μg/ml of SNA or both lectins at 400μg/ml of each lectin, and viral 228 
binding was performed at 4°C and bound viruses were visualized by confocal 229 
immunofluorescence microscope. The level of virus on the cell surface was also quantified 230 
by measuring the fluorescence intensity. Lectin treatment resulted in a significant decrease 231 
of viral binding to PT cells (Fig.6). This further confirmed that BTV binds cell surface sialic 232 
acids during entry. 233 
To address if BTV entry into insect cells also utilizes sialic acids, we similarly examined the 234 
distribution of α2,3- and α2,6-linked sialic acids on the surface of Culicoides derived KC 235 
cells. In addition, since mosquito C6/36 cells are also susceptible to BTV infection in the 236 
laboratory (17), we included the C6/36 cells in the analysis. Both KC and C6/36 cells 237 
appeared to express exclusively α2,6-linked sialic acids, as demonstrated by 238 
immunofluorescence staining with the specific lectins (Fig.7A). Further, BTV infection of 239 
these cells in the presence of the two inhibitors confirmed further that MALII, the inhibitor of 240 
α2,3-linked sialic acids had almost no inhibitory effect, while SNA, the inhibitor of α2,6-linked 241 
sialic acids, inhibited 90% of progeny virus production in a dose-dependent manner (Fig. 242 
7B). To eliminate the possibility that the effect was due to cell cytotoxicity, we performed the 243 
MTT assay, which showed no impact on the viability of cells (Fig. 7C). These data suggest 244 
that BTV utilizes α2,6-linked sialic acid for entry into the KC and C6/36 cells.  245 
Taken together, the data demonstrate that α2,3- and α2,6-linked sialylated glycans play a 246 
major receptor role for BTV entry in both mammalian and insect cells although the role of  247 
other receptors cannot be excluded, particularly for KC and C6/36 cells, as previous studies 248 
have indicated that VP2 is not essential for infection and that the integrin binding RGD motif 249 
present on the VP7 protein could be responsible for the process (18, 19). 250 
 251 















































In order to locate the sialic acid binding sites on VP2, hydrogen deuterium exchange mass 253 
spectrometry (HDX-MS) was used. Deuterium exchange with hydrogen atoms in VP2 protein 254 
prepared in D2O buffer, followed by quenching, proteolysis, and peptide detection by MS 255 
allows an assessment of the dynamic change of VP2 protein conformation upon SA binding. 256 
Purified VP2 was incubated with 3’-sialyl-N-acetyllactosamine (Neu5Acα2,3Galβ1-4GlcNAc) 257 
and digested by pepsin and aspergillopepsin prior to HDX-MS analysis. After carefully 258 
optimising the quenching condition, a total number of 126 peptides were identified, yielding 259 
an overall VP2 sequence coverage of 63.1% (Fig.8A). Ligand-induced alteration of the H/D 260 
exchange rate was only observed in two peptides, peptide 114-124 (DAQPLKVGLDD) of 261 
VP2 was de-protected, while peptide 185-194 (VAYTLKPTYD) was protected in the 262 
presence of the glycan, suggesting that peptide VAYTLKPTYD is involved in sialic acid 263 
binding (Fig.8B). To confirm the data, we introduced substitution mutations in this peptide, 264 
targeting specifically the two highly conserved residues Y187 and K190 followed by 265 
attempted virus rescue by reverse genetics. Of two substitutions at Y187, one to 266 
phenylalanine and the other to alanine, only the Y187F mutant was recovered as viable 267 
virus. The substitution of Y187A failed to recover virus. Similarly, mutations at K190 to 268 
aspartic acid or to alanine failed to recover infectious progeny virus consistent with Y187 and 269 
K190 being critical for virus fitness (Fig.9A) and also consistent with a role in receptor 270 
binding. To verify that these lethal mutations did not alter the overall structure and key 271 
function of VP2, mutant proteins Y187A, K190D and K190A were expressed in BSR cells by 272 
transfecting with capped mutant S2 RNA segments. The expression of three mutant proteins 273 
and ability to trimerize, was not compromised, indicating that these mutations did not perturb 274 
the overall structure of the protein (Fig.9B). To substantiate this hypothesis, each of these 275 
mutant proteins was expressed as recombinant baculovirus and each purified protein was 276 
incorporated into polyvalent nanoparticles.  However, none of these three mutant protein 277 
nanoparticles showed any hemagglutination activity with sheep RBCs, in contrast to that of 278 
the WT or Y187F mutant proteins (Fig.9C). These results are consistent with a role for the 279 
















































BTV generally has very low receptor binding avidity, which is reflected by its low 282 
hemagglutinin activity (10). Thus, the identification of BTV receptor binding using the virus 283 
itself or the purified recombinant VP2 protein has been quite challenging. We have 284 
circumvented that by successfully generating protein nanoparticle displaying with multivalent 285 
presentation of VP2. Such VP2-PNP had significantly enhanced avidity of VP2 interaction 286 
with glycans. This is the first tailored design of protein nanoparticle scaffolds for multivalent 287 
presentation of a non-enveloped viral glycoprotein, which has been proven a powerful tool 288 
for studying of virus-receptor interaction. 289 
We used glycan array to identify that recombinant VP2 binds both α2,3- and α2,6-linked 290 
sialic acids with an overall higher affinity to α2,3-linked sialic acids. During a natural BTV 291 
transmission cycle, VP2 mediates BTV binding to sheep erythrocytes via blood meals by the 292 
Culicoides vector. Sheep erythrocytes show almost exclusively α2,3-linked sialic acid (20). 293 
Treatment with MALII resulted in hemagglutination of sheep RBCs but treatment of SNA did 294 
not (data not shown). Therefore, the particularly high abundance of α2,3-linked sialic acid on 295 
sheep erythrocytes could serve as the primary target of infection. 296 
Glycan array showed that VP2 binds both Neu5Ac and Neu5Gc sialoglycans with α2,3- and 297 
α2,6-linkage. Trypsin treatment had shown no effect on the ability of BTV hemagglutination 298 
of human erythrocytes (21) and the ability of VP2 binding to L929 cells (10), suggesting that 299 
VP2 binds to O-linked glycans containing sialic acids. Despite an overall stronger binding to 300 
α2,3-linked sialic acid, inhibition of α2,6-linked sialic acid demonstrated a significant effect on 301 
progeny virus production in three different mammalian cells corresponding to a predominant 302 
distribution of α2,6-linked sialic acid on all three mammalian cell lines. Baby hamster kidney 303 
cells (BHK-21) generally express high level of Neu5Ac and low level of Neu5Gc, while ovine 304 
and bovine cells express high level of Neu5Gc but less Neu5Ac (22). All three cell lines 305 
could be effectively infected by BTV, though VP2 showed a preference of binding to Neu5Ac 306 















































allow efficient virus attachment and entry into host mammalian cells. Moreover, treatment of 308 
MALII or SNA or a combination of both lectins effectively prevented viral binding to the 309 
surface of PT cells, confirming that both α2,3- and α2,6-linked sialic acids are directly 310 
involved in virus attachment and entry. Notably, PT cells is more sensitive to the treatment 311 
with both lectin competitors targeting α2,3- and α2,6-linked sialic acids compared to BSR 312 
and MDBK cells. The data was consistent with the immunofluorescence confocal microscopy 313 
analysis, which confirmed that there is greater amount of both linked sialic acids on the 314 
surface of PT cells, therefore they are more susceptible to BTV infection. This may also 315 
explain why BTV has a wide cell tropism in tissue culture cells. However, the very specific 316 
host species tropisms of BTV indicated that there are likely some other factors involved. 317 
Insect cells generally do not produce sialylated glycoproteins (23). However, the presence of 318 
a functional cytidine monophosphate- (CMP-) Sia synthase (CSAS) had been detected in 319 
Ae. Aegypti, and dengue virus (DENV) was found to recognize α2,6- linked sialic acid 320 
structures on the surface of mosquito tissues, suggesting its potential key roles during the 321 
early DENV-vector interactions (24). Since the complete genomic sequence of Culicoides 322 
sonorensis is now available (25), we were able to identify two transcripts CSON006402-1 323 
and CSON006950-1 encoding two 426aa and 427aa undefined proteins, which are 324 
predicted to function as beta-galactoside alpha-2,6-sialytransferase by PANTHER algorithm 325 
(http://www.pantherdb.org/). In this study, we demonstrated that both Culicoides KC and Ae. 326 
Albopictus C6/36 cells express exclusively α2,6-linked sialic acid, which plays a major role 327 
for BTV entry although other putative receptors may be involved.  328 
Our previous structural data predicted the existence of putative sialic acid binding sites on 329 
the hub domain of VP2 and other putative binding sites on the tip domain for unknown 330 
receptors (5). Unlike other dsRNA viruses, such as rotavirus or mammalian reovirus (26), the 331 
BTV VP2 trimer has a triskelion shape composed of three tip domains protruding from a 332 
central hub domain, which is essential to prevent activation of the underlying membrane 333 















































body and tip domains protected in the presence of sialoglycan Neu5Acα2,3Galβ1-4GlcNAc 335 
in the HDX-MS. Therefore, we predicted that sialic acid binding site is most likely located at 336 
the peptide VAYTLKPTYD and may extends into connecting region in each of the three tip 337 
domains (Fig.8C). We confirmed the conserved residues Y187 and K190 are critical for sialic 338 
acid binding using virus recovery assay in combination with mutagenesis and 339 
hemagglutination assay.  340 
This study revealed sialic acids as functional receptor and the different role of α2,3- and 341 
α2,6-linked sialic acid for BTV infection in both mammalian cells and insect cells, also 342 
provided biochemical evidence not only to support the structural data but also to reveal 343 
dynamic changes of VP2 during receptor binding. Inhibitors targeting specific sialic acid or 344 
putative binding sites could be developed as potent antivirals. However, it does not exclude 345 
the possibility that other more generic receptors such as heparan sulphate proteoglycan, 346 
integrin may also be used by BTV. Whether it is cell or strain dependent, remain to be further 347 
investigation.  348 















































Materials and Methods 350 
Cloning and protein expression 351 
Synthetic strep-pA-LS and strep-Fc sequences were purchased from Eurofins Genomics. 352 
Strep-pA-LS was ligated into the pCAGG-PM1 vector using the PacI/AflII sites. Strep-Fc and 353 
BTV1 VP2 sequences (Protein Data Bank accession number: 3J9D) were inserted into the 354 
BamHI site of baculovirus transfer vector pAcYM1 by Gibson Assembly (NEB). HEK293 cells 355 
were transfected with pCAG-strep-pA-LS using polyethylenimine (PEI). 5 days post-356 
transfection, supernatant was collected and the pA-LS protein was purified using the Strep-357 
Tactin Superflow Plus (Qiagen). Recombinant baculovirus expressing Fc-VP2 was 358 
generated by co-transfecting the pAcYM1-strep-Fc-VP2 and Bacmid DNA into S. frugiperda 359 
(Sf9) cells. Sf9 cells were then infected with recombinant baculoviruses at an MOI of 2 for 48 360 
h at 28°C. Cells was then pelleted, lysed in lysis buffer (50mM Tris-HCl pH 8.0, 200mM 361 
NaCl, 1mM EDTA, 1% NP-40) and Fc-VP2 protein was purified from the lysate using the 362 
Strep-Tactin Superflow Plus (Qiagen). 363 
 364 
Glycerol gradient ultracentrifugation 365 
200μl of Fc-VP2 or Fc-VP2-PNP complex containing 10% glycerol were centrifuged on a 366 
15% to 45% continuous glycerol gradient at 55,000 rpm for 1h at 4°C. Gradient was then 367 
fractionated by collecting the samples from top. Each fraction was then analyzed by SDS-368 
PAGE followed by western blotting using a rabbit anti-strep II tag antibody (Abcam).  369 
 370 
Hemagglutination assay 371 
Purified Fc-VP2 at various concentrations was incubated with 1 μg or 2 μg of pA-LS for 30 372 
min at room temperature to allow binding of Fc-VP2 to the pA-LS nanoparticles. 25μl of the 373 















































washed sheep erythrocytes (Thermo Fisher Oxoid Ltd.) in V-shaped bottom 96-well plates 375 
and incubated for 1h at room temperature as previously described (4). Hemagglutination of 376 
RBC was visualized as a lack of sedimentation to a distinct red pellet and HA titres were 377 
calculated as the reciprocal of the lowest positive dilution. PBS dilution buffer was used as 378 
negative control. 379 
 380 
ELISA based glycophorin binding assay 381 
96-well Nunc MaxiSorp ELISA plates (Thermofisher) were coated with 1μg of glycophorin A 382 
(Sigma) per well diluted in 50μl of carbonate coating buffer (15mM Na2CO3, 36mM NaHCO3, 383 
pH9.6) and incubated overnight at 4°C. The plates were washed with PBS with 0.05% 384 
Tween-20 (PBST) and blocked with 5% skimmed milk in PBST for 1 h at room temperature. 385 
Different amount of Fc-VP2 alone or Fc-VP2-PNPs complex formed with 2μg of pA-LS were 386 
then added to allow binding to glycophorin A. Bound VP2 was detected with a rabbit anti-387 
VP2 pAb and then alkaline phonsphatase-labeled anti-rabbit secondary antibody (Sigma). 388 
The reaction was developed with the substrate p-nitrophenyl phosphate disodium (Thermo 389 
Scientific), and the optical density was determined at 405nm.  390 
 391 
Glycan array analysis 392 
2 μg of pA-LS and 2 μg of Fc-VP2 or 2 μl of pA-LS alone as negative control were mixed in 393 
50 μl of PBS with 0.1% BSA and incubated for 30 min at room temperature to allow 394 
formation of Fc-VP2-PNPs. Additional PBS supplemented with Tween-20 was added to 395 
make the final volume of 70 μl containing 0.05% Tween-20 and 0.1% BSA. The reaction 396 
mixture was applied on the slide (NCFG Glycan Array v3.0) and incubated for 1 h at room 397 
temperature in a dark humidified chamber. Slide was washed with PBST, and then 398 
incubated with rabbit anti-VP2 antibody diluted at 1:500 in PBST and 0.1% BSA at room 399 















































Immuno Research) at 5 μg/ml in PBST and 0.1% BSA was added and incubated for 1 h at 401 
room temperature. Slides were scanned with InnoScan 1100AL scanner (resolution: 402 
5μm/pixel, Alexa 647: PMT85/Laser Power High) with data processing using Mapix 8.2.7 403 
software (Innopsys, Chicago, IL). For each set of six replicate spots, the mean and S.D. 404 
were calculated after the highest and lowest values were excluded.  405 
 406 
Immunofluorescence 407 
Monolayer cells grown overnight on the coverslips were fixed in 4% paraformaldehyde and 408 
then incubated with FITC-conjugated lectin MAL II or SNA diluted at 1:500 or 1:1000 in 409 
PBST for 1 h at room temperature. Nuclei were stained with Hoechst. Images were then 410 
captured using the LSM800 inverted confocal microscope (Carl Zeiss Ltd.). 411 
 412 
Flow cytometry analysis 413 
Cells were trypsinized, resuspended at 1X106 in PBS and fixed with 4% paraformaldyhyde. 414 
The fixed cells were incubated with FITC-conjugated lectin MALII or SNA diluted at 1:500 or 415 
1:1000 in PBS for 1h at room temperature. Measurement of cells without labelling was 416 
included as a negative control. Fluorescence for cells was excited with the 488nm laser on a 417 
BD LSR II flow cytometer (BD Biosciences). At least 1X104 cells were analyzed for each 418 
sample. 419 
 420 
MTT cytotoxicity assay 421 
Monolayer cells seeded in 96 well plates were treated with 100, 200, 400, 600 or 800 μg/ml 422 
of MALII and SNA lectins or a combination of both at 400μg/ml of each lectin for 2h prior to 423 
addition of 20μl of 5mg/ml 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-424 















































removed and 150μl of MTT solvent (4mM HCl, 0.1% NP-40 in isopropanol) was added. 426 
Plates were covered, agitated gently on a shaker for 15 min and then read at 590nm by a 427 
plate reader. Experiment was performed in triplicate and the percentage of cell viability was 428 
calculated. 429 
 430 
Lectin competition assay 431 
Monolayer cells seeded in 48 well plates were treated with 100, 200 or 400μg/ml of MALII 432 
and SNA lectins or a combination of both at 400μg/ml of each for 1h at 4°C prior to infection 433 
of BTV serotype 1 at an MOI of 1.0 for 24h at 37°C (mammalian cells) or 28°C (insect cells). 434 
Supernatant virus was then collected and virus titre was determined by plaque assay. 435 
 436 
Viral binding assay 437 
Monolayer cells grown on coverslips were mock-treated or pre-treated with 400μg/ml of 438 
MALII, 400μg/ml of SNA or both lectins at 400μg/ml of each lectin for 1h at 4°C. Viral binding 439 
at an MOI of 10 was performed on ice in the absence or presence of lectin inhibitors. After 440 
washing off the unbound viruses, bound viruses were labelled with rabbit anti-BTV primary 441 
antibody (1:1000 dilution) and secondary goat anti-rabbit Alexa Fluor 488 (1:2000 dilution, 442 
Thermofisher) and visualized by LSM800 inverted confocal microscope (Carl Zeiss Ltd). A 443 
quantitative assessment of the levels of BTV on the cell surface was measured as 444 
normalized integrated fluorescence intensity using the Fiji software. 445 
 446 
Hydrogen Deuterium Exchange Mass Spectrometry (HDX-MS) 447 
HDX-MS was carried out using an automated HDX robot (LEAP Technologies, Fort 448 
Lauderdale, FL, USA) coupled to an M-Class Acquity LC and HDX manager (Waters Ltd., 449 















































of 3’-sialyl-N-acetyllactosamine (Neu5Acα2,3Galβ1-4GlcNAc) in equilibration buffer (10mM 451 
potassium phosphate buffer pH7.4) was added to 135 μl of deuterated buffer (10mM 452 
potassium phosphate buffer pD7.4) and incubated at 4°C for 60, 120, 600 or 4200s. 453 
Following the labelling reaction, samples were quenched by adding 50 μl of the labelled 454 
solution to 100 μl quench buffer (100mM potassium phosphate, pH2.4 with formic acid, 0.2% 455 
n-Dodecyl-β-D-Maltopyranoside (DDM)). 50 μl of quenched sample was passed through an 456 
online proteolysis column containing a 1:1 mixture of immobilised pepsin and 457 
aspergillopepsin (Type XIII protease) [NovaBioAssays, USA] at 500 μl/min and a VanGuard 458 
Pre-column Acquity UPLC BEH C18 (Waters Ltd.) for 3 min. The resulting peptic peptides 459 
were transferred to a C18 column (Waters Ltd.) and separated by gradient elution of 0-40% 460 
MeCN (0.1% v/v formic acid) in H2O (0.3% v/v formic acid) over 7 min at 40 μl/min. The HDX 461 
system was interfaced to a Synapt G2Si mass spectrometer (Waters Ltd.). HDMSE and 462 
dynamic range extension modes (data independent analysis (DIA) coupled with IMS 463 
separation) were used to separate peptide prior to CID fragmentation in the transfer cell. 464 
HDX data were analysed using PLGS (v 3.0.2) and DynamX (v 3.0.0) software supplied with 465 
the mass spectrometer. Restrictions for identified peptides in DynamX were as follows: 466 
minimum intensity 1000, minimum products per amino acid 0.3, max sequence length 25, 467 
max ppm error 5, file threshold 4/5. 468 
 469 
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Figure Legends 550 
Figure 1. Fc-VP2 and pA-LS nanoparticle form complex. (A) SDS-PAGE with coomassie 551 
blue staining confirmed the purity and correct size of purified recombinant pA-LS protein. (B) 552 
SDS-PAGE with coomassie blue staining showing the native Fc-VP2 protein largely in 553 
trimeric form in the absence of heat and DTT reducing agent. (C) Migration of Fc-VP2 in the 554 
presence or absence of pA-LS nanoparticles in a 14-45% continuous glycerol gradient 555 
showing the formation VP2 and nanoparticle complex, Fc-VP2-PNP. 556 
 557 
Figure 2. Optimization of binding between Fc-VP2 and pA-LS nanoparticle. (A) The HA titres 558 
of variable amounts of Fc-VP2 combined with 1μg or 2μg of pA-LS were measured using 559 
0.25% of washed sheep RBCs. Highlight shows the maximum HA titres with the combination 560 
of 2.5μg of Fc-VP2 and 2μg of pA-LS or 1.25 μg of Fc-VP2 and 1μg of pA-LS. (B) The HA 561 
titres of 2.5μg of Fc-VP2 combined with variable amounts of pA-LS were measured using 562 
0.25% of washed sheep RBCs. Highlight shows the maximum HA titre obtained with the 563 
combination of 2.5μg of VP2-Fc and 2μg of pA-LS. (C) Glycohrorin A (1μg) binding of 564 
variable amounts of Fc-VP2 plus 2 μg of pA-LS or Fc-VP2 alone were measured by ELISA 565 
assay showing the significantly higher binding affinity by the complex  compared to Fc-VP2. 566 
 567 
Figure 3. VP2 nanoparticles, assembled as described, were used for analysis of glycan 568 
binding to glycan arrays of the Functional Glycomics Gateway as described. Relative binding 569 
to a subset of glycans, of 562 total, is shown. Symbols to the right of the figure identify 570 
individual sugars present within the glycan chains shown.  571 
 572 
Figure 4. Distribution of α2,3- and α2,6-linked sialic acids on the surface of BSR, PT and 573 















































microscope using FITC-conjugated MALII and SNA, which specifically bind to α2,3- and 575 
α2,6-linked sialic acids respectively. Sialic acids is shown in green and nuclei stained with 576 
Hoechst shown in blue. The insets at the bottom right corner show an enlarged version of 577 
single cell staining from the area enclosed by the dashed line. Scale bar = 20μM. (B) FITC-578 
conjugated MALII and SNA labelled cell surface sialic acids measured by flow cytometry 579 
shown in histogram (left) and then quantified and shown as median fluorescence intensity 580 
(right). 581 
 582 
Figure 5. Inhibitory effect of specific lectins on BSR, PT and MDBK cells. (A) MTT 583 
cytotoxicity assay showed no significant cytotoxicity effect at the concentrations of lectins 584 
tested. (B) Inhibitory effect of MALII or SNA or a combination of both at different 585 
concentration on progeny BTV production in virus infected BSR, PT and MDBK cells. 586 
Statistical analysis: two-way ANOVA test (n=3) *p<0.05, **p<0.01, ***p<0.001, ns p>0.05. 587 
 588 
Figure 6. Viral binding to PT cells was inhibited in the presence of 400μg/ml of MALII or 589 
400μg/ml of SNA or both lectins at 400μg/ml of each lectin. Lectin treated cells were 590 
incubated with BTV at an MOI of 10 at 4°C. The bound viruses were labelled with anti-BTV 591 
antibody and visualized by confocal immunofluorescence microscope. BTV is shown in 592 
green and nuclei stained with Hoechst shown in blue. The insets at the bottom right corner 593 
show an enlarged version of cells staining from the area enclosed by the dashed line. The 594 
normalized fluorescence intensity of cell surface BTV was measured by Fiji software and 595 
plotted as histogram. Two-way ANOVA test ***p<0.001. 596 
 597 
Figure 7. Inhibitory effect of specific lectins on KC and C6/36 cells. (A) Immunofluorescence 598 
showing the distribution of α2,3- and α2,6-linked sialic acids on the surface of KC and C6/36 599 















































sialic acids respectively. Sialic acids shown in green and nuclei stained with Hoechst shown 601 
in blue. The insets at the top right corner show an enlarged version of single cell staining 602 
from the area enclosed by the dashed line. Scale bar = 10μM. (B) Inhibitory effect of MALII 603 
and SNA or a combination at different concentration on progeny virus production in BTV 604 
infected KC and C6/36 cells. (C) MTT cytotoxicity assay showed no significant cytotoxicity 605 
effect at the concentrations of lectins tested. Statistical analysis: two-way ANOVA test (n=3) 606 
***p<0.001, ns p>0.05. 607 
 608 
Figure 8.  HDX-MS reveals potential sialic acid binding site in VP2. (A) Coverage of 609 
peptides from VP2 identified (blue boxes) by HDX-MS after digestion with pepsin and 610 
aspergillopepsin in series. (B) Peptide DAQPLKVGLDD and peptide VAYTLKPTYD showing 611 
protection (solid line red box) and de-protection (hatched red box) respectively in the 612 
presence of the sialoglycan 3’-sialyl-N-acetyllactosamine in HDX. Conserved amino acid 613 
residues Y187 and K190 within peptide VAYTLKPTYD are predicted to bind sialic acid (red 614 
arrow). (C) Predicted sialic acid binding sites (yellow) and residues Y187 and K190 (pink) 615 
are located at the tip domains of VP2 trimer. 616 
 617 
Figure 9.  Mutations at two highly conserved residues result in failure of virus recovery and 618 
loss of VP2 hemagglutination activity. (A) BTV reverse genetics containing each mutant S2 619 
or WT S2 were performed in BSR cells. Plaque assay shows the virus recovery failed with 3 620 
mutants Y187A, K190D and K190A while Y187F develops virus plaques similar phenotype 621 
to that of WT at 72h post-transfection. (B) SDS-PAGE following by western blotting with a 622 
rabbit anti-VP2 antibody showing similar expression level and trimerization of VP2 mutant 623 
(Y187A, K190D and Y190A) proteins with that of WT VP2 protein in BSR cells transfected 624 
with capped WT or mutant S2 RNA segments. (C) SDS-PAGE with coomassie blue staining 625 















































K190D and K190A) protein similar to the WT Fc-VP2 protein (left). However, recombinant 627 
Fc-VP2 mutant (Y187A, K190D and K190A) protein incorporated into polyvalent 628 
nanoparticles was unable to agglutinate sheep RBCs in contrast to the WT and Y187F 629 
mutant Fc-VP2 protein (right). 630 
 631 
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